BLUE bluebird bio Inc

Price (delayed)

$4.43

Market cap

$367.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.04

Enterprise value

$579.03M

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - ...

Highlights
The gross profit has soared by 82% YoY and by 28% from the previous quarter
The EPS has surged by 53% year-on-year and by 27% since the previous quarter
The revenue has surged by 85% year-on-year but it has declined by 2.7% since the previous quarter
The quick ratio has plunged by 60% YoY but it has grown by 25% from the previous quarter
bluebird bio's equity has plunged by 82% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
82.91M
Market cap
$367.29M
Enterprise value
$579.03M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
-$35.75M
EBIT
-$453.84M
EBITDA
-$447.78M
Free cash flow
-$446.06M
Per share
EPS
-$6.04
Free cash flow per share
-$5.47
Book value per share
$2.06
Revenue per share
-$0.44
TBVPS
$6.31
Balance sheet
Total assets
$520.1M
Total liabilities
$361.24M
Debt
$278.21M
Equity
$158.86M
Working capital
$33.71M
Liquidity
Debt to equity
1.75
Current ratio
1.27
Quick ratio
1.2
Net debt/EBITDA
-0.47
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-83.3%
Return on equity
-185.9%
Return on invested capital
-93.6%
Return on capital employed
-115.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
1.84%
1 week
-2.42%
1 month
-13.48%
1 year
-12.8%
YTD
-35.98%
QTD
-35.98%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
-$35.75M
Gross profit
-$47.37M
Operating income
-$214.9M
Net income
-$453.86M
Gross margin
N/A
Net margin
N/A
The revenue has surged by 85% year-on-year but it has declined by 2.7% since the previous quarter
The gross profit has soared by 82% YoY and by 28% from the previous quarter
bluebird bio's operating income has soared by 64% YoY and by 24% from the previous quarter
The company's net income rose by 47% YoY and by 24% QoQ

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
2.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 53% year-on-year and by 27% since the previous quarter
bluebird bio's equity has plunged by 82% YoY and by 12% from the previous quarter
BLUE's P/B is 28% below its 5-year quarterly average of 3.0 but 8% above its last 4 quarters average of 2.0
The revenue has surged by 85% year-on-year but it has declined by 2.7% since the previous quarter

Efficiency

How efficient is bluebird bio business performance
bluebird bio's ROE has plunged by 137% YoY and by 32% from the previous quarter
bluebird bio's ROA has decreased by 50% YoY and by 5% from the previous quarter
bluebird bio's return on invested capital has decreased by 20% YoY but it has increased by 15% QoQ

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The total assets is 44% greater than the total liabilities
The total assets has dropped by 61% year-on-year and by 9% since the previous quarter
The quick ratio has plunged by 60% YoY but it has grown by 25% from the previous quarter
bluebird bio's debt is 75% more than its equity
bluebird bio's equity has plunged by 82% YoY and by 12% from the previous quarter
bluebird bio's debt has soared by 53% YoY but it has decreased by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.